Integrin
All Product Categories
-
Integrin Inhibitors
(185)
View all products
-
Integrin Agonists
(5)
View all products
-
Integrin Antagonists
(68)
View all products
-
Integrin Activators
(6)
View all products
-
Integrin Modulators
(5)
View all products
-
Integrin Inducers
(2)
View all products
-
Integrin Degrader
(1)
View all products
-
Integrin Controls
(3)
View all products
-
Integrin Substrate
(1)
View all products
-
Integrin Ligands
(15)
View all products
-
Integrin Produits associés (382)
Produits associés (382)
-
αvβ1 integrin-IN-2
0 ImagesCat. No.: HY-156521CAS No.: 2234874-68-9
-
FR-158999
0 ImagesCat. No.: HY-19275CAS No.: 160138-41-0FR-158999 is a potent orally active fibrinogen inhibitor. FR-158999 exhibits potent anti-platelet activities with a pIC50 of 7.50. FR-158999 can be used for antithrombotic research.
-
UR-3216
0 ImagesCat. No.: HY-122230CAS No.: 220386-65-2UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
-
pUR4
0 ImagesCat. No.: HY-P12080CAS No.: 176365-43-8pUR4 is a recombinant peptide that acts as a fibronectin (FN) inhibitor. pUR4 binds to the N-terminal type I modules of fibronectin, inhibiting the polymerization of soluble fibronectin and its deposition into the extracellular matrix (ECM). pUR4 reduces β1 integrin activation by depleting ECM fibronectin and disrupting FN-β1 integrin coupling. pUR4 attenuates TNF-α-induced endothelial hyperpermeability, maintains endothelial monolayer integrity, and reduces TNF-α-induced cell morphological changes. pUR4 decreases neutrophil adhesion to cardiac endothelial cells, T cell interstitial migration, immune cell infiltration, collagen deposition, and fibroblast activation. pUR4 can be used in research on pathological vascular leakage, heart failure, inflammation, chronic kidney disease, liver fibrosis, and intestinal fibrosis.
-
FK 633
0 ImagesCat. No.: HY-19175CAS No.: 147865-49-4Synonyms: FR-144633FK 633 (FR-144633) is a fibrinogen inhibitor and peptide mimetic GPⅡbⅡa receptor antagonist. FK 633 has anti-platelet and anti-thrombotic effects. FK 633 inhibits ADP-, collagen-, thrombin-, and PAF-induced platelet aggregation with IC50 values of 103, 87, 98, and 239 nM, respectively.
-
MK-0668
0 ImagesCat. No.: HY-12159CAS No.: 865110-07-2MK-0668 is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
-
Tirofiban-d9
0 ImagesCat. No.: HY-17369BSCAS No.: 1332075-40-7Synonyms: L700462-d9; MK383-d9Tirofiban-d9 is deuterium labeled Tirofiban.
-
Elarofiban
0 ImagesCat. No.: HY-10315CAS No.: 198958-88-2Synonyms: RWJ-53308Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
-
BGC0222
0 ImagesCat. No.: HY-P10783BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors.
-
ICAM-1988
0 ImagesCat. No.: HY-122192CAS No.: 444169-80-6ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity.
-
LVTX-8
0 ImagesCat. No.: HY-P10988CAS No.: 2197957-07-4LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model.
-
XV459
0 ImagesCat. No.: HY-117177CAS No.: 170902-52-0XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research.
-
iRGD-CPT
0 ImagesCat. No.: HY-161095iRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer.
-
Excisanin A
0 ImagesCat. No.: HY-136699CAS No.: 78536-37-5Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.
-
Anti-CD11b Antibody (ICRF44)
0 ImagesCat. No.: HY-P991836Anti-CD11b Antibody (ICRF44) reacts with the human CD11b. Anti-CD11b Antibody (ICRF44) recognizes the α subunit of the CD11b/CD18 complex, an α/β heterodimeric surface glycoprotein on human leukocytes. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
Anti-CD11a/LFA-1α Antibody (R7-1)
0 ImagesCat. No.: HY-P990871Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human CD11a/LFA-1α. Anti-CD11a/LFA-1α Antibody (R7-1) can neutralize LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-CD11a/LFA-1α Antibody (R7-1) can be used for the research of inflammation.
-
Euchrestaflavanone A
0 ImagesCat. No.: HY-125123CAS No.: 80510-05-0Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis.
-
VIP236
0 ImagesCat. No.: HY-164429CAS No.: 2418533-90-9VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors.
